

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**Form 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of May, 2015

Commission File Number: 001-37368

---

**ADAPT IMMUNE THERAPEUTICS PLC**

(Translation of registrant's name into English)

---

**91 Park Drive, Milton Park  
Abingdon, Oxfordshire OX14 4RY  
United Kingdom**  
(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

---

---

**Other Events**

On May 12, 2015, Adaptimmune Therapeutics plc (the "Company") issued a press release announcing that it has strengthened its senior management team with the appointment of William (Will) Roberts as Vice President, Investor Relations. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.

On May 13, 2015, the Company issued a press release announcing that it will present data at the 18th Annual American Society of Gene and Cell Therapy (ASGCT) Meeting. The press release is attached as Exhibit 99.2 and is incorporated by reference herein.

**Exhibits**

99.1 Press release dated May 12, 2015

99.2 Press release dated May 13, 2015

2

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Adaptimmune Therapeutics plc**

By: /s/ Margaret Henry  
Name: Margaret Henry  
Title: Corporate Secretary





## Adaptimmune Announces Appointment of New Vice President of Investor Relations

OXFORD, UK and PHILADELPHIA, Pa., May 12, 2015 — Adaptimmune (NASDAQ: ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it has strengthened its senior management team with the appointment of William (Will) Roberts as Vice President, Investor Relations.

Mr. Roberts will lead the company's investor communications strategies, along with involvement in wider communication programs and activities.

Mr. Roberts brings over 20 years of investor relations, communications, and scientific experience in small, global mid-cap and large cap biotechnology companies to Adaptimmune. He spent ten years (2004-2014) with ViroPharma Incorporated (acquired by Shire in 2014) with responsibility for investor and media relations, patient and physician advocacy, certain branded communications regarding Cinryze® (C1 esterase inhibitor [human]) and other commercial products, and disease awareness, culminating in his service as Vice President, Corporate Communications. His record includes developing award-winning communications programs such as ViroPharma's investor relations program which won IR Magazine's 2013 'IR Professional of the Year — Small Cap' and 'Grand Prix, Best Overall Investor Relations Program — Small Cap' awards. Previously, Mr. Roberts spent 12 years (1992-2004) with MedImmune Inc. (acquired by AstraZeneca in 2007) in various scientific and investor relations roles of increasing responsibility. Most recently, he served as Vice President, Investor Relations and Corporate Communications for Discovery Labs.

"I am delighted to welcome Will to Adaptimmune," said James Noble, Chief Executive Officer of Adaptimmune. "Adaptimmune has only recently evolved into a public company, and his wealth of communications experience in U.S. biotechnology companies that have been highly lauded for their investor communications programs and transparency will be essential in order for us to continue our evolution."

Mr. Roberts said, "Adaptimmune has come a long way in a short amount of time, thanks to its remarkable people and technology. I am thrilled to join this excellent team, and look forward to contributing as we move forward."

### About Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the company aims to utilize the body's own machinery — the T cell — to target and destroy cancer cells by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune's lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June 2014, Adaptimmune

---

announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. The Company currently has over 100 employees.

### Forward-Looking Statements

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and other words of similar meaning. These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Prospectus filed with the Securities and Exchange Commission on May 7, 2015. We urge you to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

### Adaptimmune Contacts

Will Roberts  
Vice President, Investor Relations  
(215) 966-6264  
E: will.roberts@adaptimmune.com

Margaret Henry  
Head of PR  
T: +44 (0)1235 430036  
Mob: +44 (0)7710 304249  
E: margaret.henry@adaptimmune.com

---



### Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting

OXFORD, UK and PHILADELPHIA, Pa., May 13, 2015 — Adaptimmune Therapeutics plc (Nasdaq: ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present data at the 18th Annual American Society of Gene and Cell Therapy (ASGCT) Meeting. The data in this presentation pertain to the phenotypic and functional evaluation of engineered T cells targeting NY-ESO-1 in the blood of patients following infusion in Phase 1/2 clinical studies in synovial sarcoma and multiple myeloma patients. This presentation follows the data on persistence and clinical responses in both studies as presented at the recent AACR conference in Philadelphia, PA in April. The ASGCT meeting will take place at the Hyatt Regency in New Orleans, Louisiana, May 13 — 16, 2015.

#### Friday, May 15, 2015

##### *Oral Presentation*

Session title: Cancer — Immunotherapy, Cancer Vaccines I

Abstract number: 551

Presenter: Luca Melchiori, Ph.D., Senior Scientist at Adaptimmune

Title: “Enhanced-affinity NY-ESO-1-specific T cells exhibit extended functionality without exhaustion in a pattern of effector and memory programming in multiple cancer indications”

Presentation Time: 3:30 pm to 3:45 pm

Location: Empire D

#### **About Adaptimmune**

Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the company aims to utilize the body’s own machinery — the T cell — to target and destroy cancer cells by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune’s lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. The company currently has over 100 employees. For more information: <http://www.adaptimmune.com>

#### **Forward-Looking Statements**

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and other words of similar meaning. These forward-looking statements involve certain risks and uncertainties. Such risks

---

and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our final Prospectus filed with the Securities and Exchange Commission on May 7, 2015. We urge you to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

#### Adaptimmune Contacts

Will Roberts  
Vice President, Investor Relations  
T: (215) 966-6264  
E: [will.roberts@adaptimmune.com](mailto:will.roberts@adaptimmune.com)

Margaret Henry  
Head of PR  
T: +44 (0)1235 430036  
Mob: +44 (0)7710 304249  
E: [margaret.henry@adaptimmune.com](mailto:margaret.henry@adaptimmune.com)

---